This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of Herbmed Plus in Patients withRenal Calculi (HerbmedPlus)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2011 by Amai Charitable Trust.
Recruitment status was:  Recruiting
Information provided by:
Amai Charitable Trust Identifier:
First received: May 16, 2011
Last updated: May 17, 2011
Last verified: May 2011

More specifically, the present invention relates to a 'Herbal Preparation' that is useful for

  • Treatment of Renal calculi
  • Reduction in the stone size & surface area
  • The expulsion of stone
  • Decreased need of Analgesic(Antiinflammatory Effect)
  • Stops the recurrence and reformation of renal

Condition Intervention Phase

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II, 28 Week, Randomized, Double- Blind, Placebo- Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 'Herbmed Plus' an Ayurvedic Formulation in Patients With Renal Calculi

Resource links provided by NLM:

Further study details as provided by Amai Charitable Trust:

Primary Outcome Measures:
  • To evaluate the efficacy of "Herbmed plus"in patients with urinary calculi by assessing the reduction in the stone size & surface area/ or the expulsion of stone [ Time Frame: In 210 days ]

Secondary Outcome Measures:
  • Reduction in the size of stone Reduction in the density of the stone Painless expulsion of the stone/fragments Reduction in pain Consumption of Analgesics [ Time Frame: In 210 days ]

Estimated Enrollment: 84
Study Start Date: April 2010
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: HERBMED PLUS
Herbal formulation of four constituents i.e.Varuna,Yav,Aghada,Kadali as per ayurvedic literature.
500 mg Twice day for 6 month with lunch and dinner.
Other Name: Herbmed plus is ayurvedic formulation

Detailed Description:
  1. Study duration 28 weeks
  2. No. of Scheduled visits 8 visits
  3. Study product Dose, Group one-:1capsule (of 500 mg) orally twice a day with meals for 24 weeks. Group two-:placebo1capsule (of 500 mg) orally twice a day with meals for 24 weeks.

Ages Eligible for Study:   10 Years to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 10-75 years (Both inclusive)
  • Patients with Renal calculi, diagnosis confirmed by plain X-ray KUB &/or ultrasound KUB/CT scan Abdomen
  • Size of the calculi ranging from 04 mm -09 mm
  • Able and willing to give written informed consent and comply with the requirements of the study protocol
  • Patients of reproductive potential (males and females) and willing to use a reliable means of contraception (e.g hormonal contraceptive patch, intrauterine device and physical barrier) throughout study participation
  • Patients will to cooperate & give consent for the trial& comes for regular follow up.

Exclusion Criteria:

  • Patients having acute condition of renal calculi.
  • Any systemic disease requiring other medications of surgery for calculus condition.
  • Complicated cases of Renal Calculi requiring surgical condition.
  • Chronic or current infectious disease such as but not limited to chronic renal infection including active urinary tract infection.Uncontrolled diabetes, hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction
  • Any other urogenital disorders.
  • Liver dysfunction, defined as total bilirubin more then 1.5 the upper limit of Normal, aspartate aminotransferase more then 2.5 upper limit of Normal, or alanine aminotransferase more then 2.5 upper limit of Normal,
  • Kidney disease, including serum creatinine level more then 1.5 upper limit of Normal,
  • Subjects on herbal supplements for stone disease (plant extracts preparations or herbal medicines etc.) within previous 3 months.
  • Participated in another clinical drug trial within 3 months before recruitment.
  • Pregnancy or breast feeding
  • Evidence of significant uncontrolled concomitant disease which in the Investigator's opinion would preclude patient participation
  • Currently active alcohol or drug abuse or history of alcohol or drug abuse within 24 weeks prior to baseline
  • Patients with psychiatric illness or other condition that would limit compliance with study requirements
  • Patients receiving or has received any investigational drug within 30 days before receiving the first dose of study medication
  • Subjects who refuse to sign the informed consent document .
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01355341

Contact: PATANKAR B PATANKAR, MS.MCH 25434063 ext 100;
Contact: SMITA S BHOYAR, BAMS CGO 25434072 ext 304

AMAI Charitable Trust's ACE Hospital Pune Recruiting
Pune, Maharashatra, India, 411004
Contact: SURESH B PATANKAR, MS.MCH.    02025434063 ext 100   
Contact: SMITA S BHOYAR, BAMS.CGO    02025434063,02025434072 ext 304   
Principal Investigator: SURESH B PATANKAR, MS.MCH         
Sponsors and Collaborators
Amai Charitable Trust
  More Information

Responsible Party: AMAI CHARITABLE TRUST'S ACE HOSPITAL PUNE, AMAI CHARITABLE TRUST Identifier: NCT01355341     History of Changes
Other Study ID Numbers: ACE/HMP-01
Study First Received: May 16, 2011
Last Updated: May 17, 2011

Keywords provided by Amai Charitable Trust:

Additional relevant MeSH terms:
Kidney Calculi
Pathological Conditions, Anatomical
Kidney Diseases
Urologic Diseases
Urinary Calculi processed this record on July 21, 2017